We exposed HCT116 human colon cancer cells to 6 h toyocamycin treatment, which was sufficient to reduce CDK9 activity (as shown by a reduction in Phospho-Pol II level, Figure 4C). This evidence concerns the gene CDK9 and malignant colon neoplasm.